Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19
Gabriella D'ettorre, Giancarlo Ceccarelli, Massimiliano Marazzato, Giuseppe Campagna, Claudia Pinacchio, Francesco Alessandri, Franco Ruberto, Giacomo Rossi, Luigi Celani, Carolina Scagnolari, Cristina Mastropietro, Vito Trinchieri, Gregorio Egidio Recchia, Vera Mauro, Guido Antonelli, Francesco Pugliese, Claudio Maria Mastroianni
Frontiers in Medicine, doi:10.3389/fmed.2020.00389
Background: Gastrointestinal disorders are frequent in COVID-19 and SARS-CoV-2 has been hypothesized to impact on host microbial flora and gut inflammation, infecting intestinal epithelial cells. Since there are currently no coded therapies or guidelines for treatment of COVID-19, this study aimed to evaluate the possible role of a specific oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Methods: We provide a report of 70 patients positive for COVID-19, hospitalized between March 9th and April 4th, 2020. All the patients had fever, required non-invasive oxygen therapy and presented a CT lung involvement on imaging more than 50%. Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group of 28 subjects received the same therapy added with oral bacteriotherapy, using a multistrain formulation.
Results: The two cohorts of patients were comparable for age, sex, laboratory values, concomitant pathologies, and the modality of oxygen support. Within 72 h, nearly all patients treated with bacteriotherapy showed remission of diarrhea and other symptoms as compared to less than half of the not supplemented group. The estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both the prevalence of patients transferred to ICU and mortality were higher among the patients not treated with oral bacteriotherapy. d'Ettorre et al. Bacteriotherapy in Treating COVID-19 Conclusions: A specific bacterial formulation showed a significant ameliorating impact on the clinical conditions of patients positive for SARS-CoV-2 infection. These results also stress the importance of the gut-lung axis in controlling the COVID-19 disease.
ETHICS STATEMENT The studies involving human participants were reviewed and approved by Ethics Committee of Policlinico Umberto I. The patients/participants provided their written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS Gd'E, GCe, and MM contributed substantially to the conception and design of the study and interpretation and wrote the manuscript. GCa, CP, FA, FR, GR, LC, CS, CM, VT, GER, and VM contributed substantially to the the acquisition of data and the analysis. GA, FP, and CMM drafted or provided critical revision of the article and provided final approval of the version to publish. GR contributed substantially to data interpretation.
ACKNOWLEDGMENTS Authors wish to thank Prof. Claudio De Simone for suggesting the rationale of the study and the dosage of administered oral bacteriotherapy. We thank all those in the Intensive Care COVID-19 Study Group and in the Infectious Diseases COVID-19 Study Group of La Sapienza University of Rome who assisted in the care of the patients in this program. We express our solidarity with those who are or have been ill with COVID-19 the health care workers on the front lines of this pandemic.
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Alhazzani, Moller, Arabi, Loeb, Gong et al., Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19), Intensive Care Med,
doi:10.1097/CCM.0000000000004363Barr, Smith, Acute diarrhea, Am Fam Physician
Bingula, Filaire, Radosevic-Robin, Bey, Berthon et al., Desired turbulence? Gut-lung axis, immunity, and lung cancer, J. Oncol,
doi:10.1155/2017/5035371Cait, Hughes, Antignano, Cait, Dimitriu et al., Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids, Mucosal Immunol,
doi:10.1038/mi.2017.75Castelli, Angelo, Lombardi, Alfonsetti, Antonosante, Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models, Aging,
doi:10.18632/aging.102927Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis,
doi:10.1016/0021-9681(87)90171-8Chiu, Bazin, Truchetet, Schaeverbeke, Delhaes et al., Protective microbiota: from localized to long-reaching co-immunity, Front Immunol,
doi:10.3389/fimmu.2017.01678Dumas, Bernard, Poquet, Lugo-Villarino, Neyrolles, The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases, Cell Microbiol,
doi:10.1111/cmi.12966Enaud, Prevel, Ciarlo, Beaufils, Wieërs et al., The gut-lung axis in health and respiratory diseases: a place for interorgan and inter-kingdom crosstalks, Front Cell Infect Microbiol,
doi:10.3389/fcimb.2020.00009Espinoza, León, Céspedes, Gómez, Canedo-Marroquín et al., Heme oxygenase-1 modulates human respiratory syncytial virus replication and lung pathogenesis during infection, J Immunol,
doi:10.4049/jimmunol.1601414Freedman, Schnadower, Tarr, The probiotic conundrum: regulatory confusion, conflicting studies, and safety concerns, JAMA,
doi:10.1001/jama.2019.22268Hashiba, Suzuki, Nagashima, Suzuki, Inoue et al., Adenovirus-mediated transfer of heme oxygenase-1 cDNA attenuates severe lung injury induced by the influenza virus in mice, Gene Ther,
doi:10.1038/sj.gt.3301540Hill-Batorski, Halfmann, Neumann, Kawaoka, The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication, J Virol,
doi:10.1128/JVI.02422-13Hosakote, Jantzi, Esham, Spratt, Kurosky et al., Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis, Am J Respir Crit Care Med,
doi:10.1164/rccm.201010-1755OCInfusino, Marazzato, Mancone, Fedele, Mastroianni et al., Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a scoping review, Nutrients,
doi:10.3390/nu12061718Leung, To, Chan, Chan, Wu et al., Enteric involvement of severe acute respiratory syndromeassociated coronavirus infection, Gastroenterology,
doi:10.1016/S0016-5085(03)01215-0Leyer, Li, Mubasher, Reifer, Ouwehand, Probiotic effects on cold and influenza-like symptom incidence and duration in children, Pediatrics Aug,
doi:10.1542/peds.2008-2666Siaarti, Percorso assistenziale per il paziente affetto da COVID-19 Sezione 1 -Procedure area critica -versione 02
Trompette, Gollwitzer, Yadava, Sichelstiel, Sprenger et al., Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis, Nat Med,
doi:10.1038/nm.3444Tseng, Lin, Wu, Chen, Chen et al., Human heme oxygenase 1 is a potential host cell factor against dengue virus replication, Sci Rep,
doi:10.1038/srep32176Wilson, Chotirmall, Bai, Rello, COVID-19: Interim Guidance on Management Pending Empirical Evidence
Yu, Tong, Shen, Fu, Lai et al., Immunodepletion with hypoxemia: a potential high-risk subtype of coronavirus disease, medRxiv,
doi:10.1101/2020.03.03.20030650
